

## **Nicotine metabolite ratio as an informed biomarker to optimize acupuncture for smoking cessation: randomised controlled trial**

Shu-min Chen <sup>1</sup>, Jia Ji <sup>1</sup>, Chai xin<sup>1</sup>, Yang Li <sup>1</sup>, Wuyuan<sup>1</sup>, Jin Chang <sup>1</sup>, MiaoZhang <sup>1</sup>, Zhen-yu Liu <sup>1</sup>, Chao-ren Tan <sup>1</sup>, Jin-sheng Yang <sup>2</sup>, Zhao Liu <sup>3#</sup>, Ying-ying Wang <sup>1#</sup>

<sup>1</sup> Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China;

<sup>2</sup> Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China;

<sup>3</sup> Department of Tobacco Control and Prevention of Respiratory Disease, China-Japan Friendship Hospital, Beijing, China;

**# Joint corresponding authors**

**Correspondence to:** Prof Ying-ying Wang, Email: [yyw261206@126.com](mailto:yyw261206@126.com) ; Dr Zhao Liu, Email: [lzlzq2004@126.com](mailto:lzlzq2004@126.com).

**Declaration of interests:** All the authors declare no conflicts of interest.

**October 10, 2024**

## 1 ABSTRACT

2 **Objective:** To evaluate the effectiveness of using nicotine metabolite ratio (NMR) as  
3 an informed biomarker to optimize acupuncture for smoking cessation.

4 **Methods:** This was a prospective, two-arm, open-label randomized controlled trial.  
5 Participants were recruited and classified as slow or normal metabolizers based on  
6 their NMR values, and were randomly assigned to high-frequency or low-frequency  
7 acupuncture groups. Acupuncture sessions were held 3 to 5 times per week for 8  
8 weeks. Minimum behavioral support was provided. The primary outcome was the  
9 12-week continuous abstinence rate assessed by urine cotinine levels. Secondary  
10 outcomes included point abstinence, treatment adherence, and adverse reactions.

11 **Results:** Between September 2018 and April 2022, 220 participants were included.  
12 Among them, 211 (95.9%) were male, and the mean (SD) age was 48.5 (11.6) years.  
13 With 0.31 as the NMR cut-off value, 70 (31.8%) were divided as normal metabolizers  
14 and 150 (68.2%) as slow metabolizers. The validated 3-month sustained abstinence  
15 was 17.3% (19/110) in the high-frequency acupuncture group, which was  
16 significantly higher than 8.2% (9/110) in the low-frequency acupuncture group  
17 (OR=3.89, 95% CI: 1.36, 8.11). In slow metabolizers, the validated 3-month sustained  
18 abstinence rate was 19.0% (15/79) in the high-frequency acupuncture, which was  
19 higher than 7.0% (5/71) in low-frequency acupuncture (OR=3.53, 95% CI: 1.03,  
20 6.13). In normal metabolizers, the validated 3-month sustained abstinence rates were  
21 12.9% (4/31) in the high-frequency acupuncture group and 10.3% (4/39) in the  
22 low-frequency acupuncture group, with high-frequency acupuncture non-inferior to  
23 low-frequency acupuncture (OR=1.11, 95% CI: 0.24, 5.17). Treatment adherence was  
24 high in both groups, and adverse reactions were infrequent. No serious adverse events  
25 were recorded.

26 **Conclusion:** This pioneering study demonstrated that NMR might be used as a  
27 biomarker to optimize acupuncture treatments for smoking cessation, particularly  
28 among slow metabolizers. This study provides valuable insights into personalized  
29 smoking cessation strategies and highlights the potential of integrating acupuncture  
30 with other interventions for improved outcomes.

31 **Key Words:** acupuncture; smoking cessation; nicotine metabolite ratio (NMR);  
32 personalized smoking cessation strategies.

- 33 **Trial Registration:** Chinese Clinical Trials Registry (No.ChiCTR1800018196),  
34 Registered 4 September 2018, ([chictr.org.cn](http://chictr.org.cn)).

## 35 **Introduction**

36 Despite substantial reductions in tobacco use since the 1960s, the prevalence of  
37 tobacco use has remained high in the China for the past decade <sup>[1]</sup>. Tobacco use brings  
38 huge health and economic losses to Chinese people. A recent large-scale population  
39 study showed that smokers had significantly higher risks of 56 diseases and 22 causes  
40 of death <sup>[2]</sup>. As a result, nearly 20% of Chinese adult men and about 3% of women  
41 will die of smoking, unless effective cessation strategies are implemented widely <sup>[3]</sup>.

42 Acupuncture, as a complementary and alternative therapy, has been utilized for  
43 smoking cessation for over 40 years internationally <sup>[4]</sup>. Our previous meta-analysis  
44 indicated that acupuncture is an effective treatment for smoking cessation, with  
45 significant improvement in both short-term (4 weeks, RR 2.37, 95% CI 1.41 to 3.97)  
46 and long-term cessation rates (beyond 6 months, RR 2.66, 95% CI 1.50 to 4.70) <sup>[5]</sup>.  
47 Particularly, our previous studies have suggested that acupuncture's abstinence rates  
48 are comparable to those of nicotine replacement therapy and more cost-effective than  
49 conventional first-line medications <sup>[6-7]</sup>. These findings support the potential of  
50 acupuncture as an affordable and effective smoking cessation tool.

51 However, enhancing the efficacy of acupuncture for smoking cessation remains a  
52 significant challenge. Recently, nicotine metabolite ratio (NMR) has emerged as a  
53 promising biomarker to optimize cessation treatments <sup>[8]</sup>. Previous studies showed  
54 that smokers with high NMR levels (normal metabolizers) tend to have faster nicotine  
55 metabolism, leading to more frequent nicotine supplementation and lower success  
56 rates in quitting smoking <sup>[9-10]</sup>. Another randomized controlled trial (RCT) showed  
57 that varenicline was more effective than nicotine replacement monotherapy for  
58 normal metabolizers but not slow metabolizers <sup>[11]</sup>. In addition, NMR was also used as  
59 a predictor to adjust the dose of smoking cessation medication <sup>[12]</sup>.

60 Despite the potential utility of NMR, no studies to date have explored its feasibility  
61 and possibility of NMR as a biomarker to optimize acupuncture for smoking  
62 cessation. To address the evidence gap, we conducted the first randomized controlled  
63 trial (RCT) to evaluate the association between acupuncture for smoking cessation  
64 and NMR. This pioneering study not only filled a significant gap in the literature but  
65 also set the groundwork for targeted and effective acupuncture-based cessation  
66 strategies.

67

## 68 **Methods**

### 69 *Design*

70 This was a prospective 2-arm, open-label, randomized controlled trial. The trial was  
71 approved by the Chinese Clinical Trial Ethics Review Committee (Grant  
72 No.ChiECRCT-20180135) and registered in the Chinese Clinical Trials Registry  
73 (Reg. No. ChiCTR1800018196). All participants provided signed informed consent  
74 before participation in the study.

### 75 *Participants*

76 This study was conducted at Institute of Acupuncture and Moxibustion, China  
77 Academy of Chinese Medical Sciences (Beijing, China), and Wangjing Hospital of  
78 China Academy of Chinese Medical Sciences (Beijing, China). Participants were  
79 recruited via trial sites, local newspapers, community events, websites, and referrals  
80 from other medical institutions.

81 Participants were included if they were age 18 to 70 years; smoked at least 10  
82 cigarettes per day for at least 1 years, had expired air carbon monoxide (CO) > 6 parts  
83 per million (ppm), had urine cotinine concentrations <100 ng/mL, and were motivated  
84 to stop smoking. Exclusion criteria included pregnancy or breastfeeding, use of  
85 stop-smoking medication during the previous 30 days, history of severe psychiatric  
86 illness, unwillingness to use acupuncture for smoking cessation, and current diagnosis  
87 of cancer or in remission from cancer for less than 1 year.

### 88 *Randomization and blinding*

89 Randomization was conducted via a central randomization system for clinical  
90 research (<http://210.73.61.115>), which was used in our previous study [6].  
91 Randomization sequences were generated using Proc Plan in SAS, version 9.3 (SAS  
92 Institute), with trial sites as the stratification factor and a block length of 5. After  
93 logging into the website, staff entered participants' sex, age, and Fagerstrom Test for  
94 Cigarette Dependence (FTCD) score, and the system generated each participant's  
95 identification number and treatment allocation via stratified block randomization. The  
96 study statistician was masked to treatment codes until the analysis of primary outcome  
97 was completed.

98

## 99 *Procedures*

100 Potential participants contacted the local study sites to obtain study details and for  
101 eligibility checks. Eligible participants were invited for a baseline visit. At the visit,  
102 after they provided a CO reading via a Bedfont Micro Smokerlyzer, and urine cotinine  
103 reading by NicAlert strips, their eligibility was confirmed, study details were  
104 discussed, and participants signed the informed consent form. They then filled in  
105 study questionnaires. After that, participants set up their target quit date (TQD),  
106 normally 2 weeks after the baseline visit.

107 Participants were then randomized into 1 of the two groups. They were also instructed  
108 to join a WeChat group for motivational support. Participants were then seen at the  
109 study center monthly for 6 months. At each visit, study forms were completed and CO  
110 readings were taken. Each follow-up visit took approximately 10 minutes.


111 During the study period, the acupuncture was provided free of charge. The study  
112 started recruitment in September 2018 and completed all follow ups in April 2022.

## 113 *Interventions*

### 114 *Acupuncture*

115 The acupuncture applied in this study was traditional Chinese acupuncture.

116 Selection of Acupoints: Baihui(GV 20), Lieque(LU 7), Hegu(LI 4), Zusanli(ST 36),  
117 Sanyinjiao(SP 6), Taichong(LR 3); add Yintangb(EX-HN 3) when there are  
118 withdrawal symptoms such as cough and runny nose and dry eyes during the  
119 withdrawal process, and add Neiguan (PC 6) when there are withdrawal symptoms  
120 such as irritability, depression, and insomnia.(**Supplementary Figure 1**)



**Supplementary Figure 1. The acupoints used in the study**  
**The main acupoints : Baihui (GV 20), Lieque (LU 7), Hegu (LI 4), Zusanli (ST 36),**  
**Sanyinjiao (SP 6), Taichong (LR 3) with Yintangb(EX-HN 3), Neiguan (PC 6)**

121

122 Acupoint Location: Refer to the Acupuncture Point Locations in the Western Pacific  
123 Region by World Health Organization [13].

124 Needle Specification: 0.25 mm × 40 mm disposable sterile needles were used  
125 (purchased from Suzhou Medical Appliance Factory in China).

126 Manipulation of Acupuncture: 75% medical ethanol cotton ball was used for local  
127 routine disinfection. Needles were horizontally inserted at Baihui (GV 20) and Lieque  
128 (LU 7) while vertically inserted at other acupoints with a depth of 25 to 50 mm. The  
129 mild reinforcing-reducing method was applied at all acupoints. The arrival of (needle  
130 sensation) was required and the same side Zusanli(ST 36) and Lieque(LU 7) was  
131 connected to with KWD-808 pulse electroacupuncture device (Changzhou Wujin  
132 Great Wall Medical Equipment Co., LTD.) with Continuous wave at a frequency of  
133 15 Hz for 20 min. Meanwhile, the needles were withdrawn quickly to avoid bleeding  
134 or hematoma.

135 Frequency: Acupuncture was given 5 times a week for high-frequency acupuncture  
136 group and 3 times a week for low-frequency acupuncture group, both lasting for 8  
137 weeks.

138 Acupuncturists: Acupuncturists in this study were all certified by Chinese Medicine  
139 Council with average acupuncture experience of 5 years; they received guidance and  
140 curriculum from the Institute of Acupuncture and Moxibustion, China Academy of  
141 Chinese Medical Sciences, to guarantee the rigor and consistency of acupuncture  
142 treatment.

### 143 ***Behavioral Support***

144 Participants were invited to join a self-help forum set up for the trial participants on  
145 WeChat, a messaging app. This was to share their experience with stopping smoking  
146 and provide mutual support via text messages. WeChat was also used for scheduling  
147 study appointments and sending appointment reminders. No other behavioral support  
148 was provided.

### 149 ***Nicotine metabolic rate***

150 In this study, 10 mL of blood was collected from the subjects' elbow veins. The blood  
151 was centrifuged at a low speed of 3000 r/min with a centrifugal radius of 13.5 cm for  
152 10 minutes. The plasma and blood cells were separated and stored in 10  
153 cryopreservation tubes, which were then marked and placed in a -80°C freezer. The  
154 concentrations of cotinine and 3-hydroxycotinine in the blood samples were measured  
155 using liquid chromatography-mass spectrometry (LC-MS) by Beijing Huizhi Taikang  
156 Pharmaceutical Technology Co., Ltd. The Nicotine Metabolic Rate (NMR) was  
157 calculated as the ratio of 3-hydroxycotinine to cotinine. We chose 0.31 as the cut-off  
158 vaule based on previous studies <sup>[14, 15]</sup>, which defined slow metabolizers as those with  
159 NMR  $\leq$ 0.31, and normal metabolizers as those with NMR  $>$ 0.31.

160

### 161 ***Measures***

162 At baseline, demographic and smoking history variables were collected, including  
163 age, sex, education, marital status, health status, cigarettes smoked per day, smoking  
164 duration and FTND. Objective measures included expired CO and urine cotinine test.  
165 At each follow-up, participants provided information on their smoking status, ratings



166 of withdrawal symptoms using the Minnesota Nicotine Withdrawal Scale, use of the  
167 allocated and non-allocated study treatments. Participants were also asked whether  
168 they experienced any of the following since the previous visit: abnormal dreams,  
169 restlessness, irritability, mouth ulcers, increased appetite, dry mouth, headache,  
170 weight gain, nausea, upper respiratory tract infection, constipation, hand tremor,  
171 fatigue, insomnia, dizziness, and difficulty concentrating. CO and urine cotinine level  
172 were also collected.

### 173 ***Outcomes***

174 The primary outcome was 12-week continuous abstinence rate, assessed by urine  
175 cotinine concentrations  $<100$  ng/mL [16]. The secondary outcome included point  
176 abstinence assessed by expiratory CO (device purchased from Bedfont Scientific  
177 Company, Maidstone, UK) of  $<6$  ppm [17]. Participants lost to follow-up were  
178 included as nonabstainers. Treatment adherence outcomes included attendance at  
179 monthly sessions. Other outcomes included ratings of treatments, monitoring of  
180 adverse reactions and recording of serious adverse events.

### 181 ***Sample size calculation***

182 At present, no studies have been conducted on the relationship between acupuncture  
183 for smoking cessation and nicotine metabolic rate, and there is no clear sample size to  
184 calculate reference values. In this study, we refer to the literature to calculate the  
185 difference in data of NMR on the efficacy of nicotine replacement therapy. According  
186 to the formula for calculating the sample size of the two groups of superiority test,  
187  $\alpha=0.05$  and  $\beta=0.2$  were taken, and 98 participants per group was calculated using  
188 PASS 15 software. Considering the 10% dropout rate, a total of 220 people was  
189 recruited.


### 190 ***Statistical analysis***

191 The measurement data are presented as means (SD). The t-test was used for  
192 comparisons which met Gaussian distribution and homogeneity of variance, whereas  
193 the nonparametric test was used for comparisons which did not meet homogeneity of  
194 variance. The categorical variables were presented with numbers (percentages), and  
195 chisquare test was used for numeral data comparisons. For primary analyses, we used  
196 the intention-to-treat approach in which participants with unknown smoking status

197 were included as nonabstainers so that all randomized participants were included. To  
 198 adjust the calculations for comparisons, OR was adjusted by age, gender, cigarettes  
 199 per day (cpd), self-score of confidence in this cessation, acupuncture frequency,  
 200 pre-treatment FTND score, and pre-treatment CO level. SPSS 26.0 statistical software  
 201 (SPSS, Inc.) was used for statistical analysis.  $P < 0.05$  was regarded as statistical  
 202 significance. The authors had no access to information that could identify individual  
 203 participants during or after data collection.

## 204 Results

205 Between September 2018 and April 2022, 258 potential participants were screened,  
 206 and 220 eligible participants were randomly assigned to 1 of the 2 study arms.  
 207 Altogether, 77 (70%) in the high-frequency acupuncture group and 85 (77.3%) in the  
 208 low-frequency acupuncture group completed the 3-month study period. **Figure 1**  
 209 showed the distribution of study dropouts over time.



**Figure 1. The flowchart of the study participants**

211 Baseline characteristics of the study population were shown in **Table 1**. Overall, there  
 212 were 211 male participants (95.9%), the mean (SD) age was 48.5 (11.6) years, and  
 213 participants smoked on average 20.5 (10.9) cigarettes per day, with smoking duration  
 214 of 27.1 (12.1) years and FTND score of 4.5 (2.3) points. No significant differences in  
 215 baseline characteristics were observed between the two groups (all  $P>0.05$ ).

216 **Table 1. Baseline characteristics of study participants**

Characteristics	High-frequency acupuncture group			Low-frequency acupuncture group			Total N=220
	Slow metabolizers (n =79)	(n =110)		Slow metabolizers (n =71)	(n =110)		
		Normal metabolizers (n =31)	Total (n =110)		Normal metabolizers (n =39)	Total (n =110)	
<b>Gender</b>							
Men	77 (97.5)	28 (90.3)	105 (97.5)	69 (97.2)	37 (94.9)	106 (96.4)	211 (95.9)
Women	2 (2.5)	3 (9.7)	5 (4.5)	2 (2.8)	2 (5.1)	4 (3.6)	9 (4.1)
<b>Age (year)</b>							
Less than 40	22 (27.8)	10 (32.3)	32 (29.1)	16 (22.5)	8 (20.5)	24 (21.8)	56 (25.4)
41 to 50	22 (27.8)	10 (32.3)	32 (29.1)	22 (31.0)	15 (38.5)	37 (33.6)	69 (31.4)
51 to 60	20 (25.3)	10 (32.3)	30 (27.3)	20 (28.1)	9 (23.1)	29 (26.4)	59 (26.8)
61 and above	15 (19.0)	1 (3.2)	16 (14.5)	13 (18.3)	7 (17.9)	20 (18.2)	36 (16.3)
Mean (SD)	48.02±11.84	47.44 ±11.53	47.46±11.45	49.44±11.82	49.55±11.11	49.44±11.82	48.50±11.64
<b>Marriage</b>							
Single	11 (13.9)	6 (19.4)	17 (15.5)	8 (11.3)	3 (7.7)	11 (10.0)	28 (12.73)
Married	65 (82.3)	24 (77.4)	89 (80.9)	63 (88.7)	33 (84.6)	96 (87.3)	185 (84.09)
Separated/divorced/ widowed	3 (3.8)	1 (3.2)	4 (3.6)	0 (0.0)	3 (7.7)	3 (2.7)	7 (3.18)
<b>Education</b>							
Primary school or Middle and high	5 (6.3)	1 (3.2)	6 (5.5)	3 (4.2)	3 (7.7)	6 (5.5)	12 (5.45)
College and higher	41 (51.9)	13 (41.9)	54 (41.9)	18(25.4)	14 (35.9)	32 (29.1)	86 (39.09)
	33 (41.8)	17 (54.8)	50 (45.5)	50(70.4)	22 (56.4)	72 (65.5)	122 (55.45)
<b>Self-reported health status</b>							
Poor	9 (11.4)	4 (12.9)	13 (11.8)	13(18.3)	6 (15.4)	19 (17.3)	32 (14.6)
Average	48 (60.8)	13 (41.9)	61 (55.5)	34 (47.9)	22 (56.4)	56 (50.9)	117 (53.2)
Good	22 (27.8)	14 (45.2)	36 (32.7)	24 (38.8)	11 (28.2)	35 (31.8)	71 (32.3)
<b>Cigarettes smoked per day</b>							
1-9	24 (30.4)	1 (3.2)	25 (25.5)	21 (29.6)	4 (10.3)	25 (22.7)	50 (22.7)
10-19	41 (51.9)	15 (48.4)	56 (56.4)	39 (54.9)	21 (53.8)	60 (54.5)	116(52.7)
20 and above	14 (17.7)	15 (48.4)	29 (18.2)	11 (15.5)	14 (35.9)	25 (22.7)	54 (245)
Mean (SD)	18.10±8.48	26.29±8.52	20.41±10.08	18.53± 9.75	24.26±9.75	20.56±11.80	20.49±10.95
<b>Smoking duration</b>							
1-9	7 (8.9)	4 (12.9)	11 (10.0)	5 (7.0)	2 (5.1)	7 (6.4)	18 (8.2)
10-1915	15 (19.0)	5 (16.1)	20 (18.2)	17 (23.9)	5 (12.8)	22 (20.0)	42 (19.1)
20-29	18 (22.8)	8 (25.7)	26 (23.6)	16 (22.5)	17 (43.6)	33 (30.0)	59 (26.8)
30 and above	39 (49.4)	14 (45.2)	53 (48.2)	33 (46.5)	15 (38.5)	48 (43.6)	101 (45.9)
Mean (SD)	26.57±11.36	21.57±11.46	26.47±11.35	27.55±12.89	27.60±12.37	27.56±12.89	27.05±12.09
<b>FTND</b>							
0-3	27 (34.2)	9 (29.0)	36 (32.7)	27 (38.0)	18 (46.2)	45 (40.9)	81 (36.8)
4-6	33 (41.8)	15 (48.4)	48 (43.6)	31 (43.7)	14 (35.9)	45 (40.9)	93 (42.3)

7 and above	19 (24.1)	7 (22.6)	26 (23.6)	13 (18.3)	7 (17.9)	20 (18.2)	46 (20.9)
Mean (SD)	4.77±2.30	4.79±2.30	4.41±2.46	4.20±2.32	3.23±2.34	4.55±2.19	4.48±2.32

217

218 With 0.31 as the NMR cut-off value, 70 (31.8%) were divided as normal metabolizers  
219 and 150 (68.2%) as slow metabolizers. The average of 18.31 (9.91) cigarettes per day  
220 for the slow metabolizers was significantly lower than that of 25.16 (11.65) for the  
221 normal metabolizers ( $P<0.05$ ). No other significant differences in baseline  
222 characteristics were observed ( $P>0.05$ ) (**Supplementary Table 1**).

223 The validated 3-month sustained abstinence rates were 17.3% (19/110) in the  
224 high-frequency acupuncture group and 8.2% (9/110) in the low-frequency  
225 acupuncture group, with high-frequency acupuncture superior to low-frequency  
226 acupuncture (OR=3.89, 95% CI: 1.36, 8.11). In addition, the validated 2-month  
227 abstinence rates were 29.1% (32/110) in the high-frequency acupuncture group and  
228 26.4% (29/110) in the low-frequency acupuncture group, with high-frequency  
229 acupuncture non-inferior to low-frequency acupuncture (OR=1.51, 95% CI: 0.72,  
230 3.12) (**Table 2**).

231 **Table 2. Validated abstinence rates by acupuncture frequency at different time points**

Primary outcome	High-frequency acupuncture group (n =110)	Low-frequency acupuncture group (n =110)	OR (95 CI)
2 months (End of Treatment)	29.1 (32/110)	26.4 (29/110)	1.51 (0.72, 3.12)
3 months (End of Study)	17.3 (19/110)	8.2 (9/110)	3.89 (1.36, 8.11)

232 **Note:** the primary outcome was self-reported continuous abstinence rate verified by urine cotinine  
233 concentrations <100 ng/mL; OR was adjusted by age, gender, self-reported health status,  
234 cigarettes per day (cpd), smoking duration, self-score of confidence in this cessation, acupuncture  
235 frequency, pre-treatment FTND score.

236

237 In slow metabolizers, the validated 3-month sustained abstinence rate was 19.0%  
238 (15/79) in the high-frequency acupuncture, which was significantly higher than 7.0%  
239 (5/71) in low-frequency acupuncture (OR=3.53, 95% CI: 1.03, 6.13). In normal  
240 metabolizers, the validated 3-month sustained abstinence rates were 12.9% (4/31) in  
241 the high-frequency acupuncture group and 10.3% (4/39) in the low-frequency

242 acupuncture group, with high-frequency acupuncture non-inferior to low-frequency  
243 acupuncture (OR=1.11, 95% CI: 0.24, 5.17)). (Table 3)

244 **Table 3. Validated abstinence rates by NMR at different time points**

Outcome	Slow metabolizers (n =150)			Normal metabolizers (n =70)		
	High-frequency acupuncture group(n=71)	Low-frequency acupuncture group(n=110)	OR (95% CI)	High-frequency acupuncture group (n=110)	Low-frequency acupuncture group(n=110)	OR (95% CI)
2 months	29.1 (23/79)	26.8 (19/71)	1.43 (0.57, 3.63)	29.0 (9/31)	25.6 (10/39)	1.06 (0.36, 3.16)
3 months	19.0 (15/79)	7.0 (5/71)	3.53 (1.03, 6.13)	12.9 (4/31)	10.3 (4/39)	1.11 (0.24, 5.17)

245 **Note:** the primary outcome was self-reported continuous abstinence rate verified by urine cotinine  
246 concentrations <100 ng/mL; OR was adjusted by age, gender, cigarettes per day (cpd), self-score  
247 of confidence in this cessation, acupuncture frequency, pre-treatment FTND score, and  
248 pre-treatment CO level.  
249

250 Treatment adherence was similar in the two study arms (Table 4). Nearly all the  
251 participants set target quit date (95.9%), and all used at least 1 acupuncture treatment.  
252 Besides, no use of any of allocated treatment was recorded in the two study arms after  
253 the initial 3 months.

254 **Table 4. Treatment adherence, % (N)**

Treatment adherence	High-frequency acupuncture group (n =110)	Low-frequency acupuncture group (n =110)	P	Total (n=220)
Set target quit date (TQD)	96.4 (106/110)	95.5 (105/110)	0.733	95.9 (211)
Used at least 1 acupuncture treatment	100.0 (110/110)	100.0 (110/110)	—	100.0 (220/220)
Used at least 80% of acupuncture treatment	82.7 (91)	86.4 (95)	0.456	84.5 (186)
Using allocated treatment during follow-up	0.0 (0)	0.0 (0)	—	0.0 (0)
Used non-allocated treatment at any time point	6.4 (7)	5.5 (6)	0.7749	5.9 (133)

255

256 Adverse reactions were infrequent (5 participants in the high-frequency group and 3  
257 participants in the low-frequency group), which included primarily local hematoma.  
258 No serious adverse events were reported in any of the two study arms.

## 259 Discussion

260 To the best of our knowledge, this was the first randomized controlled trial to use  
261 NMR as an informed biomarker to improve the efficacy of acupuncture for smoking

262 cessation, offering significant insights for future research and clinical practice. Our  
263 findings demonstrated that high-frequency acupuncture was more effective for slow  
264 metabolizers, while low-frequency acupuncture efficacy did not differ significantly  
265 between slow and normal metabolizers. This suggests that NMR might be a crucial  
266 biomarker for tailoring acupuncture treatments, particularly for slow metabolizers.

267 The overall abstinence rates in our study align with previous researches [18-20]  
268 indicating that acupuncture is an effective intervention for smoking cessation. Our  
269 findings support acupuncture's role as an effective alternative to conventional  
270 smoking cessation therapies such as nicotine replacement therapy (NRT) and  
271 varenicline. However, the abstinence rates observed in our study were relatively  
272 modest compared to some pharmacological interventions [21], suggesting that  
273 acupuncture might be best utilized in conjunction with other treatments for optimal  
274 results.

275 The role of NMR as a biomarker in our study provided novel insights into the  
276 personalization of smoking cessation strategies. Slow metabolizers ( $NMR \leq 0.31$ )  
277 exhibited higher abstinence rates with high-frequency acupuncture compared to  
278 low-frequency acupuncture. This finding suggests that slow metabolizers might  
279 benefit more from intensive acupuncture interventions. Conversely, no significant  
280 differences were observed between high-frequency and low-frequency acupuncture  
281 among normal metabolizers ( $NMR > 0.31$ ), indicating that other factors might  
282 influence their cessation outcomes . These results<sup>[22,23]</sup> also align with previous studies  
283 showing that normal metabolizers have lower success rates with standard cessation  
284 therapies due to their rapid nicotine clearance.

285 Furthermore, the interaction between NMR and acupuncture points to a complex  
286 biochemical and physiological process. Nicotine metabolism, primarily governed by  
287 the CYP2A6 enzyme, affects how quickly nicotine is processed in the body [24]. Slow  
288 metabolizers, with lower CYP2A6 activity, maintain higher nicotine levels for  
289 extended periods, potentially experiencing less severe withdrawal symptoms.  
290 High-frequency acupuncture might further alleviate withdrawal symptoms and  
291 cravings in these individuals by modulating neurotransmitter release and enhancing  
292 endorphin levels [25], thereby supporting smoking cessation.

293 In contrast, normal metabolizers break down nicotine rapidly, leading to more  
294 pronounced withdrawal symptoms and cravings, which might not be adequately  
295 addressed by acupuncture alone. This highlights the need for additional support,  
296 possibly integrating pharmacological treatments like nicotine replacement therapy or  
297 varenicline, to improve cessation outcomes in this group.

298 The identification of NMR as a predictive biomarker for acupuncture efficacy could  
299 revolutionize personalized smoking cessation strategies. By tailoring acupuncture  
300 frequency and intensity based on an individual's metabolic rate, healthcare providers  
301 can enhance treatment efficacy, reduce relapse rates, and optimize resource allocation.  
302 This approach aligns with the broader trend towards personalized medicine,  
303 emphasizing the customization of healthcare interventions based on individual  
304 characteristics.

305 The high adherence rates and low incidence of adverse reactions further underscore  
306 acupuncture's feasibility and safety as a smoking cessation tool. Participants'  
307 engagement with the WeChat support group also highlights the potential of  
308 integrating digital health interventions to enhance treatment adherence and support<sup>[26]</sup>.

309 Despite the promising results, our study has several limitations. First, the sample size,  
310 while calculated based on existing literature, might not fully capture the variability in  
311 NMR and its impact on acupuncture efficacy. Future studies with larger sample sizes  
312 are needed to validate our findings. Second, the study population consisted  
313 predominantly of male participants, which limits the generalizability of our results to  
314 female smokers. Third, the study relied on self-reported smoking status verified by  
315 urine cotinine concentrations which, despite being standard practice, may introduce  
316 some biases<sup>[27]</sup>. Fourth, another external event affecting the trial was the COVID-19  
317 pandemic. The lockdowns made the collection of CO readings and urine cotinine  
318 difficult. This reduced the validated quit rates, but both study arms were affected  
319 equally. This event was the likely reason for quit rates being lower than expected in  
320 our power calculations. Another limitation is the potential for unmeasured  
321 confounding variables that could influence both NMR and smoking cessation  
322 outcomes. While we adjusted for known confounders, there may be other factors not  
323 accounted for that could impact the relationship between NMR and acupuncture

324 efficacy. Future research should aim to identify and control for these variables to  
325 provide a clearer understanding of the mechanisms at play.

326 In conclusion, our study provides pioneering evidence that NMR can be used to  
327 optimize acupuncture treatments for smoking cessation, particularly among slow  
328 metabolizers. Further research should explore the underlying mechanisms of NMR's  
329 influence on acupuncture efficacy and extend these findings to more diverse  
330 populations. Integrating acupuncture with other behavioral and pharmacological  
331 interventions may also enhance smoking cessation outcomes, offering a  
332 comprehensive approach to tackling this significant public health issue.

333 **Primary funding:** China Capital Health Development Special Project (2024-2-4372);  
334 China Youth Qihuang Fund Special Project (11055); Science and Technology  
335 Innovation Project of China Academy of Chinese Medical Sciences (CI2021A03506);  
336 China Capital Health Development Special Project (2023-1-4281)

### 337 **Reference**

- 338 [1] World Health Organization. WHO report on the global tobacco epidemic, 2023:  
339 protect people from tobacco smoke. Geneva: World Health Organization, 2023.
- 340 [2] Chan KH, Wright N, Xiao D, Guo Y, Chen Y, Du H, et al. Tobacco smoking and  
341 risks of more than 470 diseases in China: a prospective cohort study. *Lancet*  
342 *Public Health*, 2022;7(12): e1014-e1026.
- 343 [3] Xiao D, Bai CX, Chen ZM, Wang C. Implementation of the World Health  
344 Organization Framework Convention on Tobacco Control in China: An arduous  
345 and long-term task. *Cancer*. 2015;121(17):3061-3068.
- 346 [4] Wang JH, van Haselen R, Wang M, Yang GL, Zhang Z, Friedrich ME, et al.  
347 Acupuncture for smoking cessation: A systematic review and meta-analysis of  
348 24 randomized controlled trials. *Tob Induc Dis*, 2019;17:48.
- 349 [5] Liu Z, Wang YY, Wu Y, Yang JS. Condition and effectiveness evaluation of  
350 acupuncture for smoking cessation. *Zhongguo Zhen Jiu*, 2015; 35 (8): 851-857  
351 (in Chinese).
- 352 [6] Wang YY, Liu Z, Wu Y, Yang L, Guo LT, Zhang HB, et al. Efficacy of  
353 Acupuncture Is Noninferior to Nicotine Replacement Therapy for Tobacco



- 354 Cessation: Results of a Prospective, Randomized, Active-Controlled Open-Label  
355 Trial. *Chest*, 2018; 153 (3): 680-688.
- 356 [7] Jang S, Lee JA, Jang BH, Shin YC, Ko SG, Park S. Clinical Effectiveness of  
357 Traditional and Complementary Medicine Interventions in Combination with  
358 Nicotine Replacement Therapy on Smoking Cessation: A Randomized  
359 Controlled Pilot Trial. *J Altern Complement Med*. 2019;25(5):526-534.
- 360 [8] Siegel SD, Lerman C, Flitter A, Schnoll RA. The Use of the Nicotine Metabolite  
361 Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current  
362 Evidence and Future Directions. *Cancer Prev Res (Phila)*. 2020; 13(3): 261-272.
- 363 [9] Kaufmann A, Hitsman B, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L,  
364 et al. Rate of nicotine metabolism and smoking cessation outcomes in a  
365 community-based sample of treatment-seeking smokers. *Addict Behav*.  
366 2015;51(2015):93-99.
- 367 [10] Ross KC, Gubner NR, Tyndale RF, Hawk LW Jr, Lerman C, George TP, et al.  
368 Racial differences in the relationship between rate of nicotine metabolism and  
369 nicotine intake from cigarette smoking. *Pharmacol Biochem Behav*.  
370 2016;148(2016):1-7.
- 371 [11] Qin R, Liu Z, Cheng AQ, Zhou XM, Su Z, Cui ZY, et al. Efficacy of varenicline  
372 or bupropion and its association with nicotine metabolite ratio among smokers  
373 with COPD. *Respirology*. 2024;29(6):479-488.
- 374 [12] Jones SK, Wolf BJ, Froeliger B, Wallace K, Carpenter MJ, Alberg AJ. Nicotine  
375 Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation:  
376 A Systematic Review. *Nicotine Tob Res*. 2022;24(5):633-642.
- 377 [13] World Health Organization, West Pacific Regional Affairs Office etc., World  
378 Health Organization Standard Acupuncture acupoint Location-Western Pacific  
379 Region, Region du Pacifique occidental, People's Health Press, 2017.
- 380 [14] Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et  
381 al. Use of the nicotine metabolite ratio as a genetically informed biomarker of  
382 response to nicotine patch or varenicline for smoking cessation: a randomised,  
383 double-blind placebo-controlled trial. *Lancet Respir Med*. 2015;3(2):131-138.

- 384 [15]Shahab L, Bauld L, McNeill A, Tyndale RF. Does the nicotine metabolite ratio  
385 moderate smoking cessation treatment outcomes in real-world settings? A  
386 prospective study. *Addiction*. 2019;114(2):304-314.
- 387 [16]Etter JF. Assessment of the accuracy of salivary cotinine readings from NicAlert  
388 strips against a liquid chromatography tandem mass spectrometry assay in  
389 self-reported non-smokers who passed carbon monoxide but failed NicAlert  
390 validation. *Addiction*. 2019;114(12):2252-2256.
- 391 [17]Soria R, Legido A, Escolano C, López Yeste A, Montoya J. A randomised  
392 controlled trial of motivational interviewing for smoking cessation. *Br J Gen  
393 Pract*. 2006;56(531):768-774.
- 394 [18]Chai X, Yang JS, Liu Z, Chen F, Yuan GH, Wu Y, et al. Effect of the different  
395 smoking cessation regimens with acupuncture on smoking withdrawal and their  
396 influence factors: a multi-center randomized controlled trial. *Zhongguo Zhen Jiu*.  
397 2019;39(12):1255-1261.(in Chinese)
- 398 [19]Yavagal PC, LN. Efficacy of Laser Auricular Acupuncture for Smoking  
399 Cessation: A randomised Controlled trial. *Sultan Qaboos Univ Med J*,  
400 2021;21(2): 275-281.
- 401 [20]Wang YY, Liu Z, Zhang O, Chen M, Huang L, Wu Y, et al. Effect of  
402 acupuncture treatment on smoking cessation in smokers from Hong Kong. *J  
403 Tradit Chin Med*. 2016;36(5):634-639.
- 404 [21]Lindson N, Theodoulou A, Ordóñez-Mena JM, Fanshawe TR, Sutton AJ,  
405 Livingstone-Banks J, et al. Pharmacological and electronic cigarette  
406 interventions for smoking cessation in adults: component network meta-analyses.  
407 *Cochrane Database Syst Rev*, 2023;9(9): CD015226.
- 408 [22]Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is  
409 associated with greater reward and heart rate increases from intravenous  
410 nicotine. *Neuropsychopharmacology*. 2012;37(6):1509-1516.
- 411 [23]Cooper RK Jr, Mahoney MC, Tiffany ST, Colder CR, Tyndale RF, Hawk LW Jr.  
412 Relationships Between the Nicotine Metabolite Ratio and Laboratory  
413 Assessments of Smoking Reinforcement and Craving Among Adults in a

- 414 Smoking Cessation Trial. *Nicotine Tob Res.* 2024;26(5):604-611.
- 415 [24]Ho MK, Mwenifumbo JC, Al Koulsi N, Okuyemi KS, Ahluwalia JS, Benowitz  
416 NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with  
417 smoking cessation treatment in African-American light smokers. *Clin Pharmacol*  
418 *Ther.* 2009;85(6):635-643.
- 419 [25]Wang Y, Zhang Y, Wang W, Cao Y, Han JS. Effects of synchronous or  
420 asynchronous electroacupuncture stimulation with low versus high frequency on  
421 spinal opioid release and tail flick nociception. *Exp Neurol.*  
422 2005;192(1):156-162.
- 423 [26]Tang J, Yang J, Liu Y, Liu X, Li L, Sun Y, et al. Efficacy of WeChat-based  
424 online smoking cessation intervention ('WeChat WeQuit') in China: a  
425 randomised controlled trial. *EClinicalMedicine.* 2023;60:102009.
- 426 [27]Zevin S, Jacob P 3rd, Benowitz N. Cotinine effects on nicotine metabolism. *Clin*  
427 *Pharmacol Ther.* 1997;61(6):649-654.

428

## 429 **Contributors**

430 All authors were involved in the planning of the study, literature review, data  
431 collection, interpretation of the findings, and manuscript preparation. Wang YY, Yang  
432 JS and Liu Z conceived and designed the study. Wang YY supervised the study. Chen  
433 SM, Ji J, Liu ZY, Yang L,Chai X,Wu Y, Chang J,Tan CR,and Zhang M contributed  
434 to the acquisition of data. Wang YY, Chen SM and Liu Z drafted the report. Chen SM  
435 did the statistical analysis. All authors revised the report and approved the final  
436 version before submission. Wang YY is the guarantor and attest that all listed authors  
437 meet authorship criteria and that no others meeting the criteria have been omitted.

## 438 **Data sharing statement**

439 Data will be available upon reasonable request to the corresponding author  
440 immediately following publication to anyone wishing to access the data.

## 441 **Declaration of interests**

442 All authors have completed the uniform disclosure form, and all the authors declared  
443 no conflicts of interest; no financial relationships with any organisations that might

444 have an interest in the submitted work; no other relationships or activities that could  
445 appear to have influenced the submitted work.


#### 446 Acknowledgments

447 The authors would like to thank the study participants, and appreciate every supporter  
448 who contributed to this study.

#### 449 **Supplementary Table 1. Baseline characteristics of study participants by NMR**

<b>Characteristics</b>	<b>Slow metabolizers (n =150)</b>	<b>Normal metabolizers (n =70)</b>	<b>Total N=220</b>	<b>P</b>
NMR	18.74 ± 8.01	44.15 ± 14.74	26.82 ± 15.48	<0.001
<b>Gender</b>				0.18
Men	146 (97.3)	65 (92.9)	211 (95.9)	
Women	4 (2.7)	5 (7.1)	9 (4.1)	
<b>Age (year)</b>				0.82
Less than 40	38 (25.3)	18 (25.7)	56 (25.4)	
41 to 50	44 (29.3)	25 (35.7)	69 (31.4)	
51 to 60	40 (26.7)	19 (27.1)	59 (26.8)	
61 and above	28 (18.7)	8 (11.4)	36 (16.3)	
Mean (SD)	48.64 ±12.09	48.20 ±10.68	48.50±11.64	
<b>Marriage</b>				0.34
Single	19 (12.7)	9 (12.9)	28 (12.7)	
Married	128 (85.3)	57 (81.4)	185 (84.09)	
Separated/divorced /widowed	3 (2.0)	4 (5.7)	7 (3.18)	
<b>Education</b>				0.56
Primary school or less	8 (5.3)	4 (5.7)	12 (5.45)	
Middle and high school	59 (39.3)	27 (38.6)	86 (39.09)	
College and higher	83 (55.3)	39 (55.7)	122 (55.45)	
<b>Self-reported health status</b>				0.75
Poor	22 (14.7)	10 (14.3)	32 (14.6)	
Average	82 (54.7)	35 (50.0)	117 (53.2)	
Good	46 (30.7)	25 (35.7)	71 (32.3)	
<b>Cigarettes smoked per day</b>				
1-9	45 (30.0)	5 (7.1)	50 (22.7)	<0.001
10-19	80 (53.3)	36 (51.4)	116(52.7)	
20 and above	25 (16.7)	29 (41.4)	54 (24.5)	
Mean (SD)	18.31 ± 9.91	25.16 ±11.65	20.49 ±10.95	

<b>Smoking duration</b>				0.83
<b>(year)</b>				
1-9	12 (8.0)	6 (8.6)	18 (8.2)	
10-19	32 (21.3)	10 (14.3)	42 (19.1)	
20-29	34 (22.7)	25 (35.7)	59 (26.8)	
30 and above	72 (48.0)	29 (41.4)	101 (45.9)	
Mean (SD)	27.12 ± 12.6	26.9 ± 10.97	27.05 ± 12.09	
<b>FTND</b>				0.82
0-3	54 (36.0)	27 (38.6)	81 (36.8)	
4-6	64 (42.7)	29 (41.4)	93 (42.3)	
7 and above	32 (21.3)	14 (20.0)	46 (20.9)	
Mean (SD)	4.45 ± 2.31	4.53 ± 3.64	4.48 ± 2.32	



**Figure 1. The flowchart of the study participants**